Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention

Table 4

Changes in CK-MB, cTnI, h-FABP, NO, and vWF levels before and after PCI in the control and trimetazidine groups, expressed as x̅ ± s.

	ΔCK-MB (U/L)	ΔcTnI (ng/mL)	Δh-FABP (ng/mL)	ΔNO (μmol/L)	ΔvWF (ng/ml)
Control group	4.77 ± 13.73	0.42 ± 0.78	0.06 ± 0.37	24.19 ± 5.85	0.43 ± 0.72
Trimetazidine group	0.23 ± 2.60	0.06 ± 0.37	0.04 ± 1.31	0.07 ± 7.90	0.19 ± 0.13
value	0.016	0.035	0.640	0.010	0.002

ΔCK-MB: change in creatine kinase-muscle/brain, ΔcTnI: change in cardiac troponin I, Δh-FABP: change in heart-type fatty acid-binding protein, ΔNO: change in nitric oxide, and ΔvWF: change in von Willebrand factor. .